>> >> Top Companies

>> >> Top Oncology Solution Companies in APAC

AngioDynamics [NASDAQ:ANGO] : Sparking A Trail Of Innovation In Oncology

Top 10 Oncology Solution Companies in APAC - 2021

As treatment advancements in oncology continue, medical firms and clinicians are modifying their approaches to redefine value and better manage cancer care. Healthcare stakeholders are reframing traditional care management strategies to balance cost, access, and quality of treatment in an evolving oncology market. Presently, researchers and manufacturers are developing more sophisticated therapeutic options that involve novel diagnostic techniques, delivery mechanisms (e.g., viral vectors), and therapeutic regimens. Intending to provide individualized treatments, precision medicine has taken the center stage wherein it heavily relies on genomic sequencing to identify biomarkers that may indicate an appropriate target for certain therapies. Besides, new treatment modalities like CAR-Ts, gene therapies, and many other treatment procedures that offer potentially curative solutions to complex diseases are doing the rounds. To that end, healthcare professionals are now embracing and adapting to the digital transformation of new technologies, communication, and education to prioritize on multidisciplinary care teams that help treat not only the physical effects of cancer but also the impacts it can have on patients’ entire lives.

Keeping in mind such drastic transitions, we have compiled this issue of Healthcare Tech Outlook in order to assist organizations in the task of finding accomplished solution providers to help them navigate the oncology treatment landscape. In this edition, we have listed Top 10 Oncology Solution Providers in APAC – 2021 to highlight the enterprises that can escalate the chances of your growth. Equipped with innovative technological capabilities, these enlisted solution providers are transforming the oncology paradigm at the cloverleaf of various disruptive technologies. Besides, the magazine comprises insights from subject-matter experts, CIOs, and CXOs in the healthcare sector on the latest industry trends, best practices, recent innovations, and highlights their expertise. We hope this issue of Healthcare Tech Outlook helps you build the partnership you and your organization need to foster an environment driven by robust and efficient technology.

We present to you HealthcareTech Outlook’s, Top 10 Oncology Solution Companies in APAC – 2021

Top Oncology Solution Companies in APAC

AngioDynamics [NASDAQ:ANGO]

AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine. These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes. The company banks on its rich history that’s deeply rooted in the heart of “Catheter Valley,” to become an industry-leading provider of high-quality medical devices used by physicians for the treatment of cancer and peripheral vascular disease around the world. Under its hood, it has a comprehensive suite of products like DuraMax® Chronic Dialysis Catheter, SmartPort+, C3 Wave* System, Xcela Plus Ports, Auryon, BioFlo Midline Catheter, among the others to serve patients across various medical realms like oncology, venous therapies, vascular interventions, midlines, ablation, and others

Biocartis [EBR: BCART]

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Its proprietary MDxIdylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market

Boston Scientific Corporation [NYSE: BSX]

Boston Scientific works collaboratively to solve healthcare’s toughest problems by developing solutions that matter most to those suffering from debilitating and life threatening conditions and the healthcare professionals who provide their care. Across 100+ countries, the company helps providers deliver care more effectively by reducing costs, increasing efficiencies, and expanding access to care in order to help more people in more places live longer, healthier lives. It goes beyond its mission of transforming patient lives by investing in the future and the well-being of its employees and the planet

Endofotonics

On a mission to provide real-time early gastrointestinal cancer diagnosis, Endofotonics has emerged as a game-changer in reducing cancer burden through earlier diagnosis. Established in 2013, Endofotonics is a spin-off by two founders from the National University of Singapore and the National University Hospital of Singapore. The company is pioneering the development of an AI-enabled platform for in-vivo real-time cancer diagnosis and improving timely medical interventions. Endofotonics is also on-route to release a medical device to support endoscopists in a diagnosis of early gastric cancer

Xylonix

Xylonix is an innovative cancer immunotherapy biotechnology company that stands head over the shoulder with its competitors through its best-in-class agent, 010DS-Zn. This flagship innovation of the company is a novel triple-action drug that kills cancer and simultaneously initiates two types of anti-tumor immunity attacks by T-cell and macrophages. With this Onco-Parthanatos technology, Xylonix kills and turns cancer into its own inflammatory antigens and initiates effective anti-cancer immune responses. 010DS-Zn is the only single-compound agent that simultaneously exerts the effects of an anti-tumor cytotoxic agent, T-cell response initiator, and macrophage response initiator

CSAM Health

CSAM is the leading provider of niche eHealth solutions in the Nordics. The company's software solutions enable healthcare providers to access relevant clinical information at the point of care. CSAM creates value through a unique blend of best-in-class innovative technology and outstanding human skills

Elekta

Elekta is pushing the boundaries of radiation therapy to improve access for advanced, high quality cancer care that offers high-end precision, is cost-effective, and efficient with precise, personalized treatments. The company's more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments

Epredia

Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific. Powered by trusted brands such as Richard-Allan Scientific, Microm, Shandon, Menzel Gläser, LabVision and Erie Scientific, Epredia has a wide breadth of solutions that have and will continue to transform the anatomical pathology market. Epredia is a global company working to improve patient outcomes by providing groundbreaking technologies

Genetron Health

Genetron Health is a leading precision oncology company in China that specializes in cancer molecular profiling, harnessing advanced technologies in molecular biology and data science to transform cancer care. Genetron has developed a comprehensive oncology platform that covers the entire spectrum of cancer management, addressing challenges ranging from early screening and molecular diagnostics to treatment recommendations and prognostic monitoring

Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. The company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma